Bluejay Diagnostics (BJDX) risk factors
Item 1A of every Bluejay Diagnostics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors51 risks6 new11 dropped12 reworded
The company faces an acute cash shortage, requiring $20 million by 2027 to avoid bankruptcy while operating with only 6 employees. Technical challenges with Symphony cartridges and specimen stability threaten the planned 2027 FDA 510(k) submission.
Filed Mar 06, 2026 - FY2024 10-K risk factors56 risks
Clinical trials and FDA submission for the Symphony platform are significantly delayed due to cash constraints and cartridge reproducibility issues. We rely heavily on single-source suppliers like Toray and contract manufacturers like SanyoSeiko without full technical know-how. We have incurred continuous net losses, including $10.0 million recently, and face going concern warnings.
Filed Mar 31, 2025